DECN's Subsidiary Initiates First in Industry Social Media Marketing Campaign for Genstrip50

Decision Diagnostics Corp.

Companies Mentioned:

Primary Exchange: PK
Under the Symbol: DECN




DECN's Subsidiary Initiates First in Industry Social Media Marketing Campaign for Genstrip50

Wednesday, November 5, 2014 9:25 AM

900,000 Current Users of J&J Lifescan Ultra Products Targeted With Expected Generation of $75 Million Annually at 20% EBITA

LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Decision Diagnostics Corp. (OTC: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters,  announced today that their Pharma Tech subsidiary has engaged the services of ATM Digital Branding, LLC ("ATM"), a Dallas, TX based, industry leading, digital marketing and branding agency.  ATM uses a proprietary process called Attract, Talk and Monetize to leverage digital tools such as social media,  social advertising, pay per click advertising,  smart website design and Web search engine optimization, to communicate information regarding its blood glucose test strip, Genstrip50, to the traditional diabetic market.

The vast majority of diabetics still purchase their daily blood glucose test strips from brick & mortal retail pharmacies. A minor migration has gravitated to on-line purchases, but nearly 3 million of the prospective GenStrip50 users still visit the local pharmacy or mass merchandiser for their monthly supply. This traditional purchase encounter is likely a function of a hesitation towards an online medical purchase. However, diabetics regularly confer through various social media channels to learn and share disease information, treatment options and, most importantly, to exchange life experiences arising from their physical challenges. The Pharma Tech digital communication program has begun to capitalize on those dialogs and join them to restructure their traditional diabetic buying process.

Keith Berman, CFO and Principal Executive of Decision Diagnostics stated that, "There exists an extensive user base of current diabetics, almost virtual unknowns to the diabetic supplies distribution networks, that would welcome the opportunity to forego their regular trip to purchase their box of test strips at the local retailer. We will assist them in arriving at the obvious decision to take advantage of the dramatic advantages of an on-line GenStrip50 purchase. This ATM Branding social media campaign has already engaged diabetic digital conversations to influence diabeticsmaking their first purchase through a coupon and a discount first purchase program. Once the overwhelming benefits of that purchase are experienced, that customer will never return to the store for their blood glucose test strip."

Social Media marketing directly targets those conversations and engages the diabetics  in real time.  The communication tools employed by the company's various interactive platforms will make GenStrip50 accessible to those already curious about an alternative acquisition process and visible to those who have never before considered purchase alternatives. Since social media is fundamentally a conversation between people sharing information about similar interests, engaging in those conversations will create awareness of product's on-line availability, trust in the reliability of that vehicle and the dramatic cost savings associated with its purchase.

Mr. Berman concluded by saying that, "This program has just recently begun and yet we are already seeing a significant impact on our sales, follow-up inquiries about Genstrip50 and on-line chatter. We anticipate a universe, where we are the only participant, generating about $75,000,000 in annual revenues and $15 million in annual profits, all low hanging fruit, available for us to seize through this social media campaign. We intend to capture all of it."

Forward-Looking Statements:

This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates," "will" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.
For further information about the Pharma Tech GenStrip50, please visit the company's Web Sites: or or

GenStrip(TM) test strips are a product of Pharma Tech Solutions, Inc., and are not manufactured, distributed, endorsed, or approved by nor associated with LifeScan, Inc. a Johnson & Johnson company, manufacturers and distributors of the OneTouch Ultra family of meters and OneTouch Ultra test strips.


Decision Diagnostics Corp.
Keith Berman
(805) 446-2973
[email protected]


SOURCE: Decision Diagnostics Corp.  

Subscribe to alerts from Investor Network